MW Farha, SS Salami - Therapeutic advances in urology, 2022 - journals.sagepub.com
Although prostate cancer (PCa) is the most commonly diagnosed cancer in men, most patients do not die from the disease. Prostate specific antigen (PSA), the most widely used …
F Preisser, MR Cooperberg, J Crook, F Feng… - European Urology …, 2020 - Elsevier
Context Intermediate-risk prostate cancer consists of a highly heterogeneous group of patients. Owing to this heterogeneity and variable prognoses, it is challenging to provide …
RA Vince Jr, R Jiang, J Qi, JJ Tosoian… - Prostate cancer and …, 2022 - nature.com
Abstract Background Decipher Biopsy is a commercially available gene expression classifier used in risk stratification of newly diagnosed prostate cancer (PCa). Currently …
Significant progress has been made in genetic and genomic testing for prostate cancer across the disease spectrum. Molecular profiling is increasingly relevant for routine clinical …
Background Personalized genomic classifiers have transformed the management of prostate cancer (PCa) by identifying the most aggressive subsets of PCa. Nevertheless, the …
Early identification and management of prostate cancer completely changed with the discovery of prostate-specific antigen. However, improved detection has also led to …
The vast majority of new prostate cancer diagnoses are low-grade tumors that are monitored by active surveillance rather than undergoing immediate treatment. However, a subset of …
Genomic and transcriptomic data have been generated across a wide range of prostate cancer (PCa) study cohorts. These data can be used to better characterize the molecular …
C Manceau, G Fromont, JB Beauval, E Barret… - Cancers, 2021 - mdpi.com
Simple Summary Recently, biomarkers have become a supplemental tool to aid in the diagnosis and evaluation of prostate cancer. Numerous biomarkers are being developed …